1. Short title This Act may be cited as the Alternatives to Prevent Addiction In the Nation Act or the Alternatives to PAIN Act . 2. Appropriate cost-sharing for qualifying non-opioid pain management drugs under Medicare part D (a) Medicare part D Section 1860D–2 of the Social Security Act ( 42 U.S.C. 1395w–102 ) is amended— (1) in subsection (b)— (A) in paragraph (1)(A), in the matter preceding clause (i), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10) ; (B) in paragraph (2)(A), in the matter preceding clause (i), by striking paragraphs (8) and (9) and inserting paragraphs (8), (9), and (10) ; and (C) by adding at the end the following new paragraph: (10) Treatment of cost-sharing for qualifying non-opioid pain management drugs (A) In general For plan years beginning on or after January 1, 2025, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in subparagraph (B))— (i) the deductible under paragraph (1) shall not apply; and (ii) such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug. (B) Qualifying non-opioid pain management drugs In this paragraph, the term qualifying non-opioid pain management drug means a drug or biological product— (i) that has a label indication approved by the Food and Drug Administration to reduce postoperative pain or any other form of acute pain; (ii) that does not act upon the body’s opioid receptors; (iii) for which there is no other drug or product that is— (I) rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of Approved Drug Products with Therapeutic Equivalence Evaluations ); and (II) sold or marketed in the United States; and (iv) for which the wholesale acquisition cost (as defined in section 1847A(c)(6)(B)), for a monthly supply does not exceed the monthly specialty-tier cost threshold as determined by the Secretary from time to time.